EU-PEARL will discuss challenges in NASH platform trials at this year’s NAFLD Summit

Dr. Juan M Pericàs, hepatologist and public health expert at the Vall d’Hebron Hospital Campus (Barcelona) and EU-PEARL’s NASH work package leader, will present the “Challenges and clinical trial scenarios in NASH specific platform trials” at this year’s NAFLD Summit on behalf of WP6. The NAFLD Summit, which will be held on September 16-17 in a virtual format, is organized by the European Association for the Study of the Liver (EASL), a medical association devoted to promoting excellence in liver research and clinical practice as well as providing education in hepatology. The NAFLD summit program will cover basic research and metabolic roots of pathogenesis,  clinical management of patients and new horizons and treatments for NAFLD.

In his presentation, Juan M. Pericàs will address the challenges and opportunities of Integrated Research Platforms (IRP) and platform trials as well as the proposed trial design for a NASH that was developed by EU-PEARL experts. Furthermore, other EU-PEARL members will participate in talks and discussions around aspects of NASH clinical development that are highly relevant for the accomplishment of EU-PEARL objectives.

Dr. Frank Tacke: promising preclinical targets.

Prof. Vlad Ratziu: Combination therapy // trial design and endpoints: current regulatory perspectives.

Prof. Quentin Anstee: Biomarkers to support clinical practice and drug development.

Sign up to stay informed


    We will process your data to deliver our quarterly updates to your inbox. You can view our Privacy Policy here or contact us at info@eu-pearl.eu